BIOMARKERS TO AID CLINICAL TRIALS FOR NEURODEGENERATIVE DISEASE

Grant number: 1132604 | Funding period: 2018 - 2022

Completed

Abstract

Alzheimer’s disease and Parkinson’s disease continue to affect more Australians every year, due to an ageing population and the lack of effective drugs currently available. Whilst these diseases present with different symptoms, we’ve discovered that they share a common underlying feature; the inability to clear certain metals and proteins from the brain. Our program aims to explore these clearance pathways in the brain and identify new targets to help us better diagnose and treat these diseases.

Related publications (4)

Scholarly works icon

Distribution of microRNA profiles in pre-clinical and clinical forms of murine and human prion disease

Lesley Cheng, Camelia Quek, Xia Li, Shayne A Bellingham, Laura J Ellett, Mitch Shambrook, Saima Zafar, Inga Zerr, Victoria A Lawson, Andrew F Hill

2021-03-25

Prion diseases are distinguished by long pre-clinical incubation periods during which prions actively propagate in the brain and c..

Scholarly works icon

L-3,4-dihydroxyphenylalanine (L-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease

Jessica L Billings, Sarah L Gordon, Tristan Rawling, Philip A Doble, Ashley I Bush, Paul A Adlard, David I Finkelstein, Dominic J Hare

2019-07-01

Treatment with the dopamine (DA) precursor l-3,4-dihydroxyphenylalanine (l-DOPA) provides symptomatic relief arising from DA dener..

Scholarly works icon

Multisite study of the relationships between antemortem [C-11]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology

Renaud La Joie, Nagehan Ayakta, William W Seeley, Ewa Borys, Adam L Boxer, Charles Decarli, Vincent Dore, Lea T Grinberg, Eric Huang, Ji-Hye Hwang, Milos D Ikonomovic, Clifford Jack, William J Jagusth, Lee-Way Jin, William E Klunk, Julia Kofler, Orit H Lesman-Segev, Samuel N Lockhart, Val J Lowe, Colin L Masters

2019-02-01

INTRODUCTION: We sought to establish the relationships between standard postmortem measures of AD neuropathology and antemortem [1..

Scholarly works icon

Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease

Barbara R Cardoso, Blaine R Roberts, Charles B Malpas, Lucy Vivash, Sila Genc, Michael M Saling, Patricia Desmond, Christopher Steward, Rodney J Hicks, Jason Callahan, Amy Brodtmann, Steven Collins, Stephen Macfarlane, Niall M Corcoran, Christopher M Hovens, Dennis Velakoulis, Terence J O'Brien, Dominic J Hare, Ashley I Bush

2019-01-01

Insufficient supply of selenium to antioxidant enzymes in the brain may contribute to Alzheimer's disease (AD) pathophysiology; th..

University of Melbourne Researchers